表皮生長(zhǎng)因子受體(EGFR)單克隆抗體
Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號(hào)UMAA757Hu24
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C7
- Ig亞型 IgG2b Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPA757Hu02-表皮生長(zhǎng)因子受體(EGFR)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/ml
- 且適物種Sus scrofa; Porcine (Pig，豬)
- 應(yīng)用WB; IHC; ICC/IF
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 326 ¥ 760 ¥ 1086 ¥ 2715 ¥ 10860
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Human Placenta Tissue; Primary Ab: 10μg/ml Mouse Anti-Human EGFR Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
FITC staining on IF;<br/>Sample: Human Hela cell; <br/>Primary Ab: 20μg/ml Mouse Anti-Human EGFR Antibody<br/>Second Ab: 5μg/ml FITC-Linked Caprine Anti-Mouse IgG Polyclonal Antibody<br/>(Catalog: SAA544Mu18)
-
AF488 staining on IF;
Sample: Hela cell
Primary Ab: 20μg/ml Mouse Anti-Human EGFR Antibody
Second Ab: 2μg/ml AF488-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu11)
-
Western Blot; Sample: Porcine Cerebrum lysate Primary Ab: 0.01μg/ml Mouse Anti-Human EGFR Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
Western Blot; Sample: Lane1: Hela cell lysate; Lane2: MCF7 cell lysate; Lane3: A431 cell lysate; Lane4: Human Placenta lysate
Primary Ab: 0.01μg/ml Mouse Anti-Human EGFR Antibody
Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)EGFR的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別EGFR。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA757Hu62 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA757Hu61 | 表皮生長(zhǎng)因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA757Hu06 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC |
| UPAA757Hu02 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; IHC; ICC/IF |
| UPAA757Hu01 | 表皮生長(zhǎng)因子受體(EGFR)多克隆抗體 | WB; ICC/IF |
| UFAA757Hu51 | 抗表皮生長(zhǎng)因子受體(EGFR)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | FCM |
| UMAA757Hu27 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB |
| UMAA757Hu29 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| URAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)重組抗體 | FCM |
| UMAA757Hu21 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC |
| UMAA757Hu23 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; ICC/IF |
| UMAA757Hu24 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC; ICC/IF |
| UMAA757Hu25 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; ICC/IF |
| UMAA757Hu22 | 表皮生長(zhǎng)因子受體(EGFR)單克隆抗體 | WB; IHC |
| USEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UHEA757Hu | 表皮生長(zhǎng)因子受體(EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEA757Hu | 抗表皮生長(zhǎng)因子受體抗體(Anti-EGFR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| ULMA757Hu | 表皮生長(zhǎng)因子受體(EGFR)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer [Wiley: source] |
| J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … [Pubmed:25249767] |
| Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands [PubMed: 26586721] |
| Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway [Pubmed:26938303] |
| analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. [pubmed:28335979] |
| Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform [Doi: 10.1016/j.talanta.2018.10.016] |
| Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers [Pubmed: 30665034] |
| Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile [Pubmed: 30919701] |
| Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents [] |
| Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study [Pubmed: 31288134] |
| Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?… [Pubmed: 31737175] |
| Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
| Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung [] | |
| Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives [] | |
| IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer [33495907] |
| European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents [33545637] |
| Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors [] |
| ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions [34914377] |
| Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies [Pubmed:35219045] |
留言咨詢(xún)
